Related Experiment Videos
Pyoderma gangrenosum associated with ulcerative colitis: response to infliximab
A López San Román1, F Bermejo, I Aldanondo
1Services of Gastroenterology, University Hospital Ramón y Cajal, Madrid, Spain.
Revista Espanola De Enfermedades Digestivas
|July 3, 2004
Summary
Pyoderma gangrenosum, a severe skin condition, can manifest in patients with inflammatory bowel disease. Infliximab demonstrated significant efficacy in healing these refractory skin lesions.
Area of Science:
- Gastroenterology and Dermatology
- Immunology
Background:
- Pyoderma gangrenosum (PG) is an inflammatory skin condition often associated with inflammatory bowel disease (IBD).
- Managing extraintestinal manifestations like PG in IBD can be challenging, especially when standard treatments fail.
Observation:
- A patient with clinically inactive ulcerative colitis developed progressive, necrotic tibial lesions consistent with pyoderma gangrenosum.
- Conventional treatments including steroids and azathioprine were ineffective in controlling the patient's skin lesions.
Findings:
- A single dose of infliximab (5 mg/kg) led to a remarkable improvement in the pyoderma gangrenosum lesions.
- Complete healing of the skin lesions was observed within 3 months of infliximab administration.
Implications:
- Infliximab shows promise as a therapeutic option for refractory pyoderma gangrenosum in IBD patients.
- This case highlights the potential of biologic therapy in managing severe extraintestinal manifestations of IBD.